Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Convalescent plasma for severe COVID-19 with acute respiratory distress syndrome
IRCT20200501047258N1Phase 3Completed
- Sponsor
- Urmia University of Medical Sciences
- Start
- May 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of COVID-19 convalescent plasma in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Urmia University of Medical Sciences. Primary endpoints: Hospitalization time, ICU admission time and 2 more. Started May 2020; status: completed.
02
Drugs
COVID-19 convalescent plasma
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20200501047258N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200501047258N1.